Compare BOC & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOC | BNTC |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.4M | 411.4M |
| IPO Year | 2010 | 2020 |
| Metric | BOC | BNTC |
|---|---|---|
| Price | $12.09 | $10.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $25.00 | ★ $27.67 |
| AVG Volume (30 Days) | 94.0K | ★ 160.8K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.61 | 80.94 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $108,274,901.00 | N/A |
| Revenue This Year | $6.06 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.49 | N/A |
| 52 Week Low | $11.30 | $9.85 |
| 52 Week High | $15.72 | $17.15 |
| Indicator | BOC | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 42.12 |
| Support Level | $12.09 | $10.10 |
| Resistance Level | $13.03 | $12.91 |
| Average True Range (ATR) | 0.29 | 0.71 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 44.57 | 9.33 |
Boston Omaha Corp is a United States based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. Company generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.